New drug trial aims to tame Parkinson's and MSA

NCT ID NCT06671938

Ongoing Disease control Sponsor: BioArctic AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY PARKINSON DISEASE

Contacts and locations

Locations

Centrum Medyczyne Neuromed Sp. z o.o.

Bydgoszcz, 85-163, Poland
Hospital Universitari General de Catalunya

Sant Cugat del Vallès, Barcelona, 08195, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, 08035, Spain
Hospital Universitario Ramón y Cajal

Madrid, Madrid, 28034, Spain
Hospital Universitario Virgen del Rocío

Seville, Andalusia, 41013, Spain
Krakowska Akademia Neurologii Sp. Z o.o

Krakow, 31-505, Poland
Policlínica Gipuzkoa

San Sebastián, 20014, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.